Nobivac SHP
Nobivac SHP
Authorised
- Canine parvovirus, strain 154, Live
- Canine adenovirus 2, strain Manhattan LPV3, Live
- Canine distemper virus, strain Onderstepoort, Live
Product identification
Medicine name:
Nobivac SHP
Active substance:
- Canine parvovirus, strain 154, Live
- Canine adenovirus 2, strain Manhattan LPV3, Live
- Canine distemper virus, strain Onderstepoort, Live
Target species:
-
Dog
Route of administration:
-
Subcutaneous use
Product details
Active substance and strength:
-
Canine parvovirus, strain 154, Live251189000.00/tissue culture infective dose 501.00Dose
-
Canine adenovirus 2, strain Manhattan LPV3, Live3162280.00/tissue culture infective dose 501.00Dose
-
Canine distemper virus, strain Onderstepoort, Live1000000.00/tissue culture infective dose 501.00Dose
Pharmaceutical form:
-
Lyophilisate and solvent for suspension for injection
Withdrawal period by route of administration:
-
Subcutaneous use
-
Dog
-
Anatomical therapeutic chemical veterinary (ATCvet) codes:
- QI07AD02
Legal status of supply:
-
Veterinary medicinal product subject to veterinary prescription
Authorisation status:
-
Valid
Authorised in:
-
Germany
Additional information
Entitlement type:
-
Marketing Authorisation
Legal basis of product authorisation:
-
Immunological veterinary medicinal product application (Article 13d of Directive No 2001/82/EC)
Marketing authorisation holder:
- Intervet Deutschland GmbH
Marketing authorisation date:
Manufacturing sites for batch release:
- INTERVET INTERNATIONAL B.V.
Responsible authority:
- Paul-Ehrlich-Institut
Authorisation number:
- 204a/97
Date of authorisation status change:
To consult adverse reactions on veterinary medicinal products please go to www.adrreports.eu/vet
Documents
Combined File of all Documents
This document does not exist in this language (English). You can find it
in another language below.
German (PDF)
Published on: 16/05/2024
How useful was this page?:
